Everand Logo

Welcome to Everand!

  • STAT

    Legendary biotech financier Sam Isaly steps down following sexual harassment allegations

    Biotech financier Sam Isaly is stepping down from OrbiMed Advisors following a barrage of sexual harassment allegations published by STAT.
    by Damian Garde Dec 08, 2017 3 minutes

    Sam Isaly, founder of biotech’s largest and most powerful biotech hedge fund, is stepping down from his leadership role at OrbiMed Advisors following a barrage of sexual harassment allegations published by STAT.

    OrbiMed put out a statement on Thursday night asserting that Isaly is retiring “pursuant to years-long succession planning discussions.” However as recently as Monday, when STAT interviewed Isaly about the allegations against him, he said there was “no planned date” for his retirement.

    Isaly’s abrupt departure comes hours after STAT sought comments from the firm about still more allegations of misconduct from

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About MDMA For PTSD, A CRISPR Treatment For Blindness, And More
    An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
    MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
    Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.

    Related Books & Audiobooks